198 related articles for article (PubMed ID: 28012116)
21. [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].
Sun CC; Zheng W; Kong CZ; Wang X; Yang CM
Zhonghua Nan Ke Xue; 2006 Oct; 12(10):904-5, 909. PubMed ID: 17121020
[TBL] [Abstract][Full Text] [Related]
22. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
[TBL] [Abstract][Full Text] [Related]
23. Correlation between age and Chromogranin A determination in prostate diseases.
Mearini L; Zucchi A; Scarponi E; Nunzi E; Aglietti MC; Bini V; Porena M
Cancer Biomark; 2011-2012; 10(3-4):117-23. PubMed ID: 22674297
[TBL] [Abstract][Full Text] [Related]
24. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
Chuang CK; Wu TL; Tsao KC; Liao SK
J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
[TBL] [Abstract][Full Text] [Related]
25. Serum tPSA, cPSA, related density parameters and chromogranin A as predictors of positive margins after radical prostatectomy.
Custovic Z; Kraus O; Tomaskovic I; Tarle M
Anticancer Res; 2007; 27(4C):2817-21. PubMed ID: 17695453
[TBL] [Abstract][Full Text] [Related]
26. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
27. Plasma chromogranin A: clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy.
Sarkar D; Singh SK; Mandal AK; Agarwal MM; Mete UK; Kumar S; Mavuduru RS; Prasad R
Cancer Biomark; 2010-2011; 8(2):81-7. PubMed ID: 21896995
[TBL] [Abstract][Full Text] [Related]
28. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis.
Ahel MZ; Kovacic K; Tarle M
Anticancer Res; 2001; 21(2B):1363-6. PubMed ID: 11396214
[TBL] [Abstract][Full Text] [Related]
29. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
30. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
[TBL] [Abstract][Full Text] [Related]
31. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.
Isshiki S; Akakura K; Komiya A; Suzuki H; Kamiya N; Ito H
J Urol; 2002 Feb; 167(2 Pt 1):512-5. PubMed ID: 11792908
[TBL] [Abstract][Full Text] [Related]
32. Response Prediction of
Rathke H; Holland-Letz T; Mier W; Flechsig P; Mavriopoulou E; Röhrich M; Kopka K; Hohenfellner M; Giesel FL; Haberkorn U; Kratochwil C
J Nucl Med; 2020 May; 61(5):689-695. PubMed ID: 31653712
[TBL] [Abstract][Full Text] [Related]
33. The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer.
Grimaldi F; Valotto C; Barbina G; Visentini D; Trianni A; Cerruto MA; Zattoni F
Int J Biol Markers; 2006; 21(4):229-34. PubMed ID: 17177161
[TBL] [Abstract][Full Text] [Related]
34. Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer.
Reis LO; Vieira LF; Zani EL; Denardi F; de Oliveira LC; Ferreira U
J Investig Med; 2010 Dec; 58(8):957-60. PubMed ID: 20818262
[TBL] [Abstract][Full Text] [Related]
35. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD
Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
Taplin ME; George DJ; Halabi S; Sanford B; Febbo PG; Hennessy KT; Mihos CG; Vogelzang NJ; Small EJ; Kantoff PW
Urology; 2005 Aug; 66(2):386-91. PubMed ID: 16098367
[TBL] [Abstract][Full Text] [Related]
37. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
[TBL] [Abstract][Full Text] [Related]
38. Tissue Chromogranin A Expression during Prostate Cancer Progression: Prediction of Chemosensitivity.
Mitsui Y; Arichi N; Hiraki M; Harada Y; Yasumoto H; Shiina H
Urol J; 2015 Jul; 12(3):2165-72. PubMed ID: 26135933
[TBL] [Abstract][Full Text] [Related]
39. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
40. Serum chromogranin-A in advanced prostate cancer.
Ferrero-Poüs M; Hersant AM; Pecking A; Brésard-Leroy M; Pichon MF
BJU Int; 2001 Nov; 88(7):790-6. PubMed ID: 11890255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]